Filtered By:
Infectious Disease: SARS
Management: National Institutes of Health (NIH)

This page shows you your search results in order of date.

Order by Relevance | Date

Total 79 results found since Jan 2013.

Study provides deeper insight into long COVID
This study is an important step toward defining long COVID beyond any one individual symptom, " said study author Dr. Leora Horwitz, director of the Center for Healthcare Innovation and Delivery Science and co-principal investigator for the RECOVER Clinical Science Core at NYU Langone Health. " This research definition — which may evolve over time — will serve as a foundation for scientific discovery and treatment design. "The researchers say studying the underlying biological mechanisms of long COVID is central to advancing informed interventions and identifying effective treatment strategies. In addition to establish...
Source: The University of Arizona: Health - May 30, 2023 Category: Universities & Medical Training Authors: mittank Source Type: research

NIH restarts bat virus grant suspended 3 years ago by Trump
Three years after then-President Donald Trump pressured the National Institutes of Health (NIH) to suspend a research grant to a U.S. group studying bat coronaviruses with partners in China, the agency has restarted the award. The new 4-year grant is a stripped-down version of the original grant to the EcoHealth Alliance, a nonprofit research organization in New York City, providing $576,000 per year. That 2014 award included funding for controversial experiments that mixed parts of different bat viruses related to severe acute respiratory syndrome (SARS), the coronavirus that sparked a global outbreak in 2002–04, a...
Source: ScienceNOW - May 8, 2023 Category: Science Source Type: news

Why It Took So Long to Finally Get an RSV Vaccine
Respiratory syncytial virus (RSV) can dangerously compromise breathing, especially for infants and the elderly. But there has been no vaccine to prevent it—until today. On May 3, the U.S. Food and Drug Administration (FDA) approved the first vaccine against RSV, from GlaxoSmithKline (GSK), to prevent respiratory disease in people ages 60 and older. The Centers for Disease Control’s vaccine committee will make formal recommendations in June about who should receive the vaccine, but GSK says it currently has enough doses to vaccinate eligible people beginning this fall. In studies involving 25,000 people that GSK...
Source: TIME: Health - May 3, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news

US National Institutes of Health Prioritization of SARS-CoV-2 Variants
Emerg Infect Dis. 2023 Apr 13;29(5). doi: 10.3201/eid2905.221646. Online ahead of print.ABSTRACTSince late 2020, SARS-CoV-2 variants have regularly emerged with competitive and phenotypic differences from previously circulating strains, sometimes with the potential to escape from immunity produced by prior exposure and infection. The Early Detection group is one of the constituent groups of the US National Institutes of Health National Institute of Allergy and Infectious Diseases SARS-CoV-2 Assessment of Viral Evolution program. The group uses bioinformatic methods to monitor the emergence, spread, and potential phenotypic...
Source: Emerging Infectious Diseases - April 13, 2023 Category: Infectious Diseases Authors: Sam Turner Arghavan Alisoltani Debbie Bratt Liel Cohen-Lavi Bethany L Dearlove Christian Drosten Will M Fischer Ron A M Fouchier Ana Silvia Gonzalez-Reiche Lukasz Jaroszewski Zain Khalil Eric LeGresley Marc Johnson Terry C Jones Barbara M ühlemann David Source Type: research

Nanoparticle with mRNA appears to prevent, treat peanut allergies in mice
Key takeawaysPeanuts are one of the most common food allergens for children.UCLA scientists have developed a nanoparticle that delivers mRNA to liver cells in order to teach the immune system to tolerate peanut protein and alleviate allergies.In mice, the nanoparticle successfully dampened symptoms of serious allergy.Peanut allergies affect 1 in 50 children, and the most severe cases lead to a potentially deadly immune reaction called anaphylactic shock.Currently, there is only one approved treatment that reduces the severity of the allergic reaction, and it takes months to kick in. A group of UCLA immunologists is aiming ...
Source: UCLA Newsroom: Health Sciences - April 3, 2023 Category: Universities & Medical Training Source Type: news

Dr. Anthony Fauci Is Stepping Down. Here ’s His Advice For His Successor
After Dr. Anthony Fauci steps down as head of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical advisor to President Biden on Dec. 31, he’ll leave behind a long and storied career. Ahead of his last day, he spoke to TIME from his office at the National Institutes of Health about what’s next for him—and his advice for whoever fills his shoes. This interview has been edited and condensed for clarity. TIME: You’re leaving your leadership positions in the federal government, but you aren’t retiring. What are you calling the next stage in your career? [time-brightc...
Source: TIME: Health - December 20, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

News at a glance: Earth ’s top geological sites, cameras on sharks, and China’s space station
NATURAL HISTORY Science society lists Earth’s top ‘geoheritage’ sites The International Union of Geological Sciences last week marked its 60th anniversary by announcing a list of 100 “geoheritage” sites that have substantially influenced understanding of Earth’s deep history . The global list, released in collaboration with UNESCO, is meant to foster conservation and tourism. The sites include familiar ones, such as the Grand Canyon’s “great unconformity,” a billion-year gap in the rock record erased by erosion. More exotic examples include limestones in Germany that preserve Arc...
Source: Science of Aging Knowledge Environment - November 3, 2022 Category: Geriatrics Source Type: research

Why the U.S. Doesn ’t Have a Nasal Vaccine for COVID-19
The U.S. led the world in quickly developing COVID-19 vaccines—one of the few bright spots in the country’s otherwise criticized response. But while injectable vaccines are effective in protecting people from getting sick with COVID-19, they are less able to block infection. In order to put the pandemic behind us, the world will need a way to stop infections and spread of the virus. That’s where a different type of vaccine, one that works at the places where the virus gets into the body, will likely prove useful. Here, though, the U.S. is losing its edge. In September, India approved a nasal COVID-19 vacc...
Source: TIME: Health - October 31, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

A New Lab-Made COVID-19 Virus Puts Gain-of-Function Research Under the Microscope
On October 14, a team of scientists at Boston University released a pre-print study reporting that they had created a version of SARS-CoV-2 combining two features of different, existing strains that boosted its virulence and transmissibility. Scientists and the public raised questions about the work, which refocused attention on such experiments, and prompted the U.S. government to investigate whether the research followed protocols for these kinds of studies. The concerns surround what is known as gain-of-function studies, in which viruses, bacteria, or other pathogens are created in the lab—either intentionally or ...
Source: TIME: Science - October 27, 2022 Category: Science Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

U.S. weighs crackdown on experiments that could make viruses more dangerous
.news-article__hero--featured .parallax__element{ object-position: 50% 40%; -o-object-position: 50% 40%; } .scroll-wrapper { overflow-x: auto; } .scroll-wrapper .news-article__figure__image{ width: 2680px; max-width: none; padding-bottom: .75rem; } .scroll-fade-before, .scroll-fade-after { position: absolute; width: 1.5rem; transition-duration: .1s; opacity: 1; } .scroll-fade-before { left: 1rem; /*margin-left: -1px;*/ background: linear-gradient(90deg, #fff, #fff 35%, hsla(0, 0%, 100%, 0)); } .scroll-fade-after { right: 1rem; /*margin-right: -1px;*/ background: linear-gradient(270deg, #fff, #fff 35%, hsla(0,...
Source: ScienceNOW - October 19, 2022 Category: Science Source Type: news

Was a study that created a hybrid COVID-19 virus too risky?
The objective was to tease apart whether Omicron’s spike protein explains why it is less pathogenic (meaning it causes less severe disease). The answer could lead to improved COVID-19 diagnostic tests and better ways to manage the disease, the preprint authors say. Somewhat surprisingly, the hybrid virus killed eight of 10 infected mice, whereas mice infected with Omicron got sick but did not die. This suggests the mutations that make Omicron less pathogenic must involve changes in proteins other than the spike protein, the authors say. What are critics of the study saying? They question the scientific val...
Source: Science of Aging Knowledge Environment - October 18, 2022 Category: Geriatrics Source Type: research

Anthony Fauci, loved and hated, plots his next move: ‘I'm not going to sit in my house’
In 1984, when Anthony Fauci took over as head of the National Institute of Allergy and Infectious Diseases (NIAID), his wife gave him a plant for the new office. Both the palm and the 81-year-old physician are still there, the giant plant now crowding the office of one of the most celebrated—and polarizing—scientific figures in U.S. history. But not for much longer. Fauci announced on 22 August that he would step down at the end of the year from both NIAID and his post as the chief medical adviser to President Joe Biden. “What am I going to do with this plant? It’s a monster. I can’t fit it in any other plac...
Source: ScienceNOW - September 1, 2022 Category: Science Source Type: news